Sebetralstat - KalVista Pharmaceuticals
Alternative Names: KVD-900Latest Information Update: 10 Jun 2025
At a glance
- Originator Vantia Therapeutics
- Developer KalVista Pharmaceuticals
- Class Amines; Aza compounds; Esters; Pyrazoles; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Hereditary angioedema
Most Recent Events
- 02 Jun 2025 Efficacy and adverse event data from the phase III KONFIDENT-S trial in Hereditary angioedema released by KalVista Pharmaceuticals
- 08 Apr 2025 KalVista Pharmaceuticals enters into licensing agreement with Kaken for the commercialization of Sebetralstat in Japan
- 25 Mar 2025 KalVista Pharmaceuticals plans to file sNDA for Sebetralstat in Hereditary angioedema in mid of 2026 (PO)